Text Size

NOW Thai HAART Study

This study has been completed.
Sponsor:
Collaborator:
Rajavithi Biomolecular Research Center
Information provided by:
Rajavithi Hospital
ClinicalTrials.gov Identifier:
NCT00367731
First received: August 22, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
  Purpose

After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.

Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.


Condition Intervention Phase
HIV
AIDS
Neurological Complications
 Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)
 Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Neurological Outcomes With in THAI National HAART Program.

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Rajavithi Hospital:

Estimated Enrollment: 500
Study Start Date: January 2005
Estimated Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV/AIDS patients.
  • Age >15 years.
  • informed consent

Exclusion Criteria:

  • Not informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00367731

Locations
Thailand
Rajavithi Hospital
Bangkok, Thailand, 10400
Lumpang Hospital
Lumpang, Thailand
Sappasithiprasong Hospital
Ubonratchathani, Thailand
Sponsors and Collaborators
Rajavithi Hospital
Rajavithi Biomolecular Research Center
Investigators
Principal Investigator: Subsai Kongsaengdao, M.D. Rajavithi Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00367731     History of Changes
Other Study ID Numbers: RVH_CER_003
Study First Received: August 22, 2006
Last Updated: August 22, 2006
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Rajavithi Hospital:
HIV
AIDS
Neurological complications
HAART

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013